New drugs will change the Prostate Cancer market

As marketing strategy consultants, it’s fascinating to watch the dynamics of a pharmaceutical market in rapid evolution.

With three new therapies for prostate cancer approved last year (cabazitaxel, denosumab, sipuleucel-T) and the approval of abiraterone acetate expected this month, the prostate cancer market is a fast changing one.

This is really good news for patients, and for a disease that effects 1 in 6 men in the United States, and is the most common non-skin cancer.

Pieter Droppert on Biotech Strategy Blog has some commentary from the recent annual meeting of the American Association for Cancer Research (AACR) on additional new products in development that may change the landscape of this disease further.

You can read more about this on Biotech Strategy Blog.

, , , , , , , , , , , , , , , , ,

error: Content is protected !!